Kiss, Gyöngyi N. and Lee, Sue-Chin and Fells, James I. and Liu, Jianxiong and Valentine, William J. and Fujiwara, Yuko and Thompson, Karin Emmons and Yates, Charles R. and Sümegi, Balázs and Tigyi, Gabor (2013) Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. BIOCHIMICA ET BIOPHYSICA ACTA, 1831 (1). pp. 117-125. ISSN 0006-3002
Text
1-s2.0-S1388198112001977-main.pdf Restricted to Repository staff only Download (806kB) | Request a copy |
Abstract
Due to its antiapoptotic action, derivatives of the lipid mediator lysophosphatidic acid (LPA) provide potential therapeutic utility in diseases associated with programmed cell death. Apoptosis is one of the major pathophysiological processes elicited by radiation injury to the organism. Consequently, therapeutic explorations applying compounds that mimic the antiapoptotic action of LPA have begun. Here we present a brief account of our decade-long drug discovery effort aimed at developing LPA mimics with a special focus on specific agonists of the LPA(2) receptor subtype, which was found to be highly effective in protecting cells from apoptosis. We describe new evidence that 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio)benzoic acid (GRI977143), a prototypic nonlipid agonist specific to the LPA(2) receptor subtype, rescues apoptotically condemned cells in vitro and in vivo from injury caused by high-dose γ-irradiation. GRI977143 shows the features of a radiomitigator because it is effective in rescuing the lives of mice from deadly levels of radiation when administered 24h after radiation exposure. Our findings suggest that by specifically activating LPA(2) receptors GRI977143 activates the ERK1/2 prosurvival pathway, effectively reduces Bax translocation to the mitochondrion, attenuates the activation of initiator and effector caspases, reduces DNA fragmentation, and inhibits PARP-1 cleavage associated with γ-irradiation-induced apoptosis. GRI977143 also inhibits bystander apoptosis elicited by soluble proapoptotic mediators produced by irradiated cells. Thus, GRI977143 can serve as a prototype scaffold for lead optimization paving the way to more potent analogs amenable for therapeutic exploration. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.
Item Type: | Article |
---|---|
Subjects: | R Medicine / orvostudomány > RM Therapeutics. Pharmacology / terápia, gyógyszertan |
Depositing User: | Prof Balázs Sümegi |
Date Deposited: | 11 Feb 2014 13:53 |
Last Modified: | 11 Feb 2014 14:58 |
URI: | http://real.mtak.hu/id/eprint/10219 |
Actions (login required)
Edit Item |